Cancer was responsible for around 142 deaths per 100,000 population in the United States in 2022. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated 65,790 deaths among men alone in 2024. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as 99 percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around 81 percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. A recent poll indicated that many U.S. adults believed smoking cigarettes and using other tobacco products increased a person’s risk of developing cancer, but a much smaller percentage believed the same for proven risk factors such as obesity and drinking alcohol.

In the period from 2017 to 2021, the incidence rate for prostate cancer among Hispanic Americans was 88.1 per 100,000 population. This statistic shows the incidence rate of prostate cancer among U.S. males from 2017 to 2021, by race and ethnicity.

In 2021, Kentucky reported the highest cancer incidence rate in the United States, with around 510 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2021.

Cancer survival statistics are typically expressed as the proportion of patients alive at some point subsequent to the diagnosis of their cancer. Statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer.

This registry contains data on Age-Adjusted Incidence Rates and Confidence Intervals for Cancer types grouped by tumor site. Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups - Census P25-1130). Since 1994, CDC’s National Program of Cancer Registries (NPCR) has funded state cancer registries to collect population-based cancer incidence data under Public Law 102-515, the Cancer Registries Amendment Act.

In the period from 2017 to 2021, approximately 513 cases of cancer per 100,000 population were reported among white males in the United States. This statistic illustrates the incidence rate of cancer in the United States for the period 2017 to 2021, by ethnic group and gender.

In the period 2018 to 2022, the death rate for prostate cancer among Hispanic Americans was 15.4 per 100,000 population. This statistic shows the death rate for prostate cancer among U.S. males from 2018 to 2022, by race and ethnicity.

This registry contains data on Age-Adjusted Incidence Rates and 95% Confidence Intervals for Brain and Other Nervous System Tumors by Histologic Grouping , Age, and Behavior. Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups - Census P25-1130). CDC’s National Program of Cancer Registries (NPCR) has funded state cancer registries to collect population-based cancer incidence data under Public Law 102-515, the Cancer Registries Amendment Act.

The rate of skin cancer in the United States increased for both sexes from 1999 to 2021, with the rate for males consistently higher than that of females. This statistic shows the incidence rate of skin cancer in the U.S. from 1999 to 2021, by gender, per 100,000 population.

Snapshot img

Multi-Cancer Early Detection Market Size 2025-2029

The multi-cancer early detection market size is forecast to increase by USD 1.29 billion at a CAGR of 15.4% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of cancer and the focus on developing innovative diagnostic tools. Next-generation sequencing technologies are revolutionizing the identification of cancer-related biomarkers, including DNA, RNA, and proteins, enabling the detection of genetic mutations at an early stage. However, limited insurance coverage poses a challenge to market growth. To address this, data analytics plays a crucial role in improving diagnostic accuracy and reducing healthcare costs. Biomarkers, whether DNA-based or protein-based, are essential for the early detection of various types of cancer. The market is expected to continue its expansion as advancements in technology and research lead to more accurate and cost-effective diagnostic solutions.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market is witnessing significant growth due to the increasing prevalence of cancer and the need for effective screening methods. Early detection of cancer can lead to improved patient survival rates and reduced mortality. Several technological advancements are driving the market. These include the use of nanotechnology for enhancing the sensitivity and specificity of diagnostic tools, big data analytics for identifying cancer-related biomarkers, and machine learning algorithms for analyzing genomic and proteomic data. Next-generation sequencing technologies, such as genome sequencing and RNA sequencing, are playing a crucial role in the discovery of genetic mutations associated with various types of cancer.
Liquid biopsies, which involve the analysis of DNA, RNA, and proteins present in bodily fluids, are gaining popularity as non-invasive screening methods for early cancer detection. Molecular signatures derived from genomic, proteomic, and biomarker data are being used to develop diagnostic tools for multi-cancer screening. These tools offer the potential for personalized treatment plans based on an individual's unique genetic profile. The integration of data from various sources, including electronic health records and wearable devices, is facilitating the development of more accurate and comprehensive diagnostic tools. This data can be analyzed using advanced data analytics techniques to identify patterns and trends that may indicate the presence of cancer.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Gene panel
  LDT
  Liquid biopsy
  Others


End-user

  Hospitals
  Diagnostic laboratories
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy
    Spain


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The gene panel segment is estimated to witness significant growth during the forecast period.

In the realm of preventive healthcare, biotechnology firms are making significant strides in the market through breakthrough device designs. Gene panel testing is a vital segment of this industry, focusing on the analysis of specific genes to identify mutations linked to various cancer types. These panels play a crucial role in personalized cancer screening and prevention by targeting inherited gene alterations. Predictive genetic testing is a key application of gene panel testing. This testing assesses inherited mutations in individuals with a family history of cancer, such as BRCA1 and BRCA2 gene mutations, which increase the risk of breast, ovarian, and other cancers.

Similarly, Lynch syndrome testing identifies mutations in mismatch repair (MMR) genes, linked to colorectal and endometrial cancers. Biotechnology companies securing venture capital investments and collaborating with national screening programs are advancing precision medicine in cancer screening. This approach tailors treatment plans based on an individual's unique genetic makeup, enhancing overall patient care. Genome science is at the forefront of these advancements, offering a more targeted and effective approach to cancer prevention and early detection. In the US market, insurance coverage for gene panel testing is expanding, making these tests more accessible to a broader population. This trend is expected to fuel the growth of the market in the coming years.

Get a glance at the market report of share of various segments Request Free Sample

The Gene panel segment was valued at USD 232.70 million in 2019 and showed a gradual increase during the foreca

In the period 2018 to 2022, a total of approximately 173 men per 100,000 inhabitants died of cancers of all kinds in the United States, compared to an overall cancer death rate of 126 per 100,000 population among women. This statistic shows cancer death rates in the U.S. for the period from 2018 to 2022, by type and gender.

There are many Biosimilar drugs such as Zirabev, Truxima, Ogiviri, Releuko, Fulphila, Retacrit, etc which are used in the effective and efficient treatment of Cancer. Monoclonal Antibodies that are used in Biosimilar drugs also have a 58% success rate in treating cancer. Overall, Biosimilar drugs are widely used in the treatment of various types of cancers such as breast cancer, lung cancer, colorectal cancer, etc. By Application:In 2022, Oncology segment dominated the US Biosimilar market. The cancer cases have been rapidly rising in the United States over the years. In 2022, the United State witnessed almost 2 million cancer cases. The rising cases of cancer also results in the demand for the development of effective and efficient treatment of cancer. The reason behind their dominance is that they have been very successful when it comes to treating life threatening diseases such as cancers. Moreover, a treatment involving these antibodies happens to be more precise than any other treatment. Furthermore, these antibodies are known for activating the immune responses for fighting a particular disease. Due to their success rates and ability to stimulate immune responses, they have gained quite a popularity in the US Biosimilar market. By Drug class:In 2022, Monoclonal Antibodies continued to dominate the US Biosimilar Market. These antibodies can be best described as proteins developed in laboratories that are known to act like actual antibodies present in our blood. Key trends by Market Segment: The United States Biosimilar Market is equipped with many domestic as well as international players. Some of the major players in the US Biosimilar Market include Pfizer, Amgen, Biogen, Viartis, and Coherus Biosciences. There are also many major hospitals that contribute to the US Biosimilar market. Some of the key hospitals include Mayo Clinic, Stanford Healthcare, UCLA Health, John Hopkins, Massachusetts General Hospitals and Cleveland Clinic. There is also the presence of regulatory bodies in US Biosimilar market ecosystem that oversee the drug development. The key organizations include Food and Drug Association (FDA), Institutional Review Board (IRB), Centre for Drug Evaluation and Research (CDER), and Office for Human Research Protections (OHRP). The US Biosimilar market is significantly growing due to various reasons such as rising geriatric population, cost effective nature of Biosimilar drugs, increasing cases of chronic diseases and growing strategic partnerships. Biosimilar drugs also tend to be cost effective. For example, Humira is a generic drug which is priced at USD 3000. Its Biosimilar drug, Amjevita, is priced way cheaper at USD 1500. Due to their affordability, they have gained popularity not only in the US but also worldwide. The geriatric population in the US has been constantly rising. The ageing population went from ~25,000 per 100,000 people in 1980s to ~54,000 per 100,000 people in 2020s. Most of the aged people cannot afford original drugs and thus, rising geriatric population raises the demand for Biosimilar drugs. Moreover, the cases of chronic diseases also have been rising in the US over the years. In 2020, there were at least 155 million people living with a chronic disease in the US. Such high number of chronic illness cases also raise the demand for the development of cost-effective medicines in the form of Biosimilar drugs. According toKen Research, the US Biosimilar Industry is anticipated to grow at a CAGR of ~40% in the next five years owing to the cost-effective nature of Biosimilar drugs, rising geriatric population, increasing cases of chronic diseases and growing strategic partnerships. TheUS Biosimilar marketis concerned with the development of such drugs which mimic the original or generics drugs. Generic drugs tend to be quite expensive and thus, many people cannot afford them. This results in demand for the development of Biosimilar drugs. Market Overview:

Data are collected under the Health Care Act 2008. The Cancer Registry collects information on all invasive (malignant) cancer diagnoses for all South Australian residents and on deaths for these cancer cases. Data include demographic information, details of the cancer including the date of diagnosis, site and histology, and the tests used to diagnose the cancer. For those cancer cases who have died, details of the cause and date of death are collected. \r Further information can be found on the SA Health website.\r

The global gynecological cancer diagnostics market size reached US$ 26.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 48.4 Billion by 2032, exhibiting a growth rate (CAGR) of 6.84% during 2024-2032. Favorable advancements in medical technology, the surging impact of demographic and lifestyle factors, continuous evolution of diagnostic technologies, rising awareness about women's health and preventive screenings, and the escalating prevalence of various types of gynecological cancer are some of the factors boosting the market growth.

IMARC Group provides an analysis of the key trends in each segment of the global gynecological cancer diagnostics market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on cancer type, test type and end-user.

United States Mammography Market size was valued at 177.55 USD Million in 2023 and is projected to reach 361.42 USD Million by 2030, growing at a CAGR of 10.25% during the forecast period 2024-2030.

United States Mammography Market Drivers

The market drivers for the United States Mammography Market can be influenced by various factors. These may include:

Rising Breast Cancer Incidence: Because breast cancer is still a major public health concern in the US, there is a constant need for early screening and detection, which is fueling the market for mammography services and products.

Technological Developments in Mammography: The accuracy and efficacy of breast cancer screening are increased by technological innovations including digital mammography, computer-aided detection (CAD) systems, and 3D mammography (tomosynthesis). These developments also result in increased adoption rates.

Healthcare regulations and Government activities: Healthcare regulations that require mammography screening for specific age groups and government activities that promote breast cancer screening and awareness can both fuel market expansion.

Growing Ageing Population: As the US population ages, older women are more likely to develop breast cancer, which raises the need for mammography services.

Growing Healthcare Expenditure: More insurance coverage for mammography screening in conjunction with growing healthcare costs in the US may lead to a rise in the use of mammography services.

Education and Awareness Campaigns: By educating the public about the value of routine breast cancer screening, healthcare organisations, advocacy groups, and governmental organisations hope to increase the number of women who get mammograms.

Technological Innovations and Product Development: As mammography technology advances, more patients and healthcare providers may choose to invest in mammography services and equipment. One example of this innovation is the creation of faster and more comfortable imaging systems.

Movement towards Personalised Medicine: The need for sophisticated diagnostic instruments like molecular breast imaging and contrast-enhanced mammography, which can offer more precise and customised diagnoses, is being driven by the movement towards personalised medicine and precision oncology.

In 2025, it was estimated that there would be over 972 thousand new cancer cases among women in the United States. This statistic illustrates the estimated number of new cancer cases and deaths in the United States for 2025, by gender.

This multi-scale map shows life expectancy - a widely-used measure of health and mortality. From the 2020 County Health Rankings page about Life Expectancy:"Life Expectancy is an AverageLife Expectancy measures the average number of years from birth a person can expect to live, according to the current mortality experience (age-specific death rates) of the population. Life Expectancy takes into account the number of deaths in a given time period and the average number of people at risk of dying during that period, allowing us to compare data across counties with different population sizes.Life Expectancy is Age-AdjustedAge is a non-modifiable risk factor, and as age increases, poor health outcomes are more likely. Life Expectancy is age-adjusted in order to fairly compare counties with differing age structures.What Deaths Count Toward Life Expectancy?Deaths are counted in the county where the individual lived. So, even if an individual dies in a car crash on the other side of the state, that death is attributed to his/her home county.Some Data are SuppressedA missing value is reported for counties with fewer than 5,000 population-years-at-risk in the time frame.Measure LimitationsLife Expectancy includes mortality of all age groups in a population instead of focusing just on premature deaths and thus can be dominated by deaths of the elderly.[1] This could draw attention to areas with higher mortality rates among the oldest segment of the population, where there may be little that can be done to change chronic health problems that have developed over many years. However, this captures the burden of chronic disease in a population better than premature death measures.[2]Furthermore, the calculation of life expectancy is complex and not easy to communicate. Methodologically, it can produce misleading results caused by hidden differences in age structure, is sensitive to infant and child mortality, and tends to be overestimated in small populations."Click on the map to see a breakdown by race/ethnicity in the pop-up: Full details about this measureThere are many factors that play into life expectancy: rates of noncommunicable diseases such as cancer, diabetes, and obesity, prevalence of tobacco use, prevalence of domestic violence, and many more.Data from County Health Rankings 2020 (in this layer and referenced below), available for nation, state, and county, and available in ArcGIS Living Atlas of the World

In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

According to the data, the rate of liver cancer diagnoses among men in 2021 was around 12 per 100,000 population, while it was five per 100,000 population among women. This statistic depicts the rate of new U.S. liver cancer diagnoses in 2021, by gender.